AFP and hepatocellular carcinoma: Importantly, miR-21 remained effective even in AFP-negative HCC cases (AUC ~0.83) and could differentiate HCC from chronic hepatitis B (AUC ~0.79) or cirrhosis (AUC ~0.81) [60].